ReviewNature reviews. Immunology2013
Immunology of age-related macular degeneration.
Review in Nature reviews. Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 391 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
391 citing papers in PubMed.
- Systemic complement activation levels in Stargardt disease.PloS one · 2021Trial
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Multiomic Integration Reveals Novel miRNA-mRNA-Protein Expression Profile in the Aged Female Retina.Investigative ophthalmology & visual science · 2026Article
- Murine models of neovascular AMD revisited: Mechanistic pathways, immune-metabolic crosstalk, and the impact of aging and sex.Experimental eye research · 2026Review
- Cynarin Alleviates Sodium Iodate-Induced Retinal Pigment Epithelium Injury by Regulating Oxidative Stress and Inflammation.Biomolecules · 2026Article
- Article
- Infiltrating Monocyte Fate Switch in Retinal Degeneration: From Early Pathology to Late Homeostasis.Research square · 2026Article
- Mitochondrial Dysfunction and Oxidative Stress in Retinal Degeneration: Mechanisms, Biomarkers, and Therapeutic Perspectives.Current issues in molecular biology · 2026Review
- Core-shell nanotherapeutics for diabetic cataract and retinopathy: current state-of-the-art and translational challenges.Drug delivery and translational research · 2026Review
- Association between optical coherence tomography biomarkers and systemic inflammatory indices in neovascular age-related macular degeneration.BMC ophthalmology · 2026Article
- Trends, hotspots, and future directions of inflammation in age-related macular degeneration: A 20-year bibliometric study.Medicine · 2026Article
- Differential associations of cataracts with somatic and cognitive-affective symptoms of depression: longitudinal findings from the English Longitudinal Study of Ageing.International ophthalmology · 2026Article
- Curcuma longa-derived extracellular vesicle-like particles ameliorate retinal neovascularization through HIF-1α and NRF2 signaling.Journal of nanobiotechnology · 2026Article
- Eccentricity-Dependent Reflectivity Rates-of-Change Across the Retina in Intermediate Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2026Article
- Caffeine intake and late dry age-related macular degeneration: tea's protective role-insights from NHANES and Mendelian randomization.International journal of retina and vitreous · 2026Article
- Shared diagnostic biomarkers and diagnostic models of age-related macular degeneration and systemic lupus erythematosus.International ophthalmology · 2026Article
- Computational aberration correction enables full-thickness retinal imaging with adaptive optics optical coherence tomography.Biocybernetics and biomedical engineering · 2026Article
- Elevated prevalence of age-related macular degeneration in a low-income urban primary care setting.Discover public health · 2026Article
- Computational modeling of intravitreal ranibizumab kinetics: Predicting macular drug concentration and half-life.PloS one · 2026Article
- Retinal pigment epithelium pathology in age-related macular degeneration: mitigation with melatonin.Frontiers in medicine · 2026Review
331 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Age-related macular degeneration (AMD) is a leading cause of blindness in aged individuals. Recent advances have highlighted the essential role of immune processes in the development, progression and treatment of AMD. In this Review we discuss recent discoveries related to the immunological aspects of AMD pathogenesis. We outline the diverse immune cell types, inflammatory activators and pathways that are involved. Finally, we discuss the future of inflammation-directed therapeutics to treat AMD in the growing aged population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.